An international team started the research project CERTAINTY in December 2023. Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to.
Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have recei
The approval of ELREXFIO is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study
ELREXFIO is the first off-the-shelf fixed-dose subcutaneous. -Today at 02:09 pm- MarketScreener
FDA Fast-Tracks Pfizer s ELREXFIO for Multiple Myeloma miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Pfizer s (PFE) ELREXFIO Receives U S FDA Accelerated Approval for R/R Multiple Myeloma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.